Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer

Fifteen patients with previously untreated extensive non-small cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (4-DMDR) at the dose of 10 mg/m2/day x 5 days every 3 weeks with routine administration of antiemetic drugs. They received a median of two courses of treatment wit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Investigational new drugs 1990-01, Vol.8 (S1), p.S73-S78
Hauptverfasser: UMSAWASDI, T, FELDER, T. B, JEFFRIES, D, NEWMAN, R. A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S78
container_issue S1
container_start_page S73
container_title Investigational new drugs
container_volume 8
creator UMSAWASDI, T
FELDER, T. B
JEFFRIES, D
NEWMAN, R. A
description Fifteen patients with previously untreated extensive non-small cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (4-DMDR) at the dose of 10 mg/m2/day x 5 days every 3 weeks with routine administration of antiemetic drugs. They received a median of two courses of treatment with the cumulative dose range from 50-712.5 mg/m2. One patient achieved partial remission with a duration of 14 weeks. Two patients had minor responses with durations of 14 and 24 weeks. Stable disease occurred in three patients (21, 22, and 27 weeks). Median survival was 33 weeks (range 3-73+ weeks). Toxicities were tolerable. Neutropenia (less than 1,000 mm3) occurred in only 16% of all treatment courses. Three patients developed correctable arrhythmias (two with atrial fibrillation and one with accelerated junctional rhythm). The cause of arrhythmia was unclear. No clinical evidence of congestive heart failure or decreased cardiac ejection fraction was observed. Nausea and vomiting were common but tolerable. Alopecia and mucositis were uncommon. Clinical pharmacokinetic studies were done in nine patients. However, plasma 4-DMDR levels were below the limit of detection (3 ng/ml). Because 4-DMDR has shown some activity in previously untreated E-NSCLC and the toxicities at this dose schedule are mild, we suggest that further studies of this drug at a higher dose in this schedule are indicated.
doi_str_mv 10.1007/BF00171988
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00171988</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2166007</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-82889d14e61d10312f6e758776a2d769c7ddc6d22a0037ddb42844d78014b48d3</originalsourceid><addsrcrecordid>eNpFkM1LAzEQxYMotVYv3oUcPAmrSTbNx1GL1UJBD3pessmsXdlmS7Jbuv-9KS0VhpmB95uB9xC6peSREiKfXuaEUEm1UmdoTKcyz4jg4hyNCRUyE1rLS3QV4y8hJNeSj9CIUSHS5Rj5z5WJgBcLHLveDbitMM8crKFbtbvBmd63oS9rW3ucahNgW7d9bAbc-y6A6cBh2HXgY70F7OoI-2--9Vlcm6bBFlJrev-DrfEWwjW6qEwT4eY4J-h7_vo1e8-WH2-L2fMys0ySLlNMKe0oB0EdJTlllQA5VVIKw5wU2krnrHCMmeQo7SVninMnFaG85MrlE_Rw-GtDG2OAqtiEem3CUFBS7DMr_jNL8N0B3vTlGtwJPYaU9PujbqI1TRWSlTqeMKEp1VTkf3yRc9I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>UMSAWASDI, T ; FELDER, T. B ; JEFFRIES, D ; NEWMAN, R. A</creator><creatorcontrib>UMSAWASDI, T ; FELDER, T. B ; JEFFRIES, D ; NEWMAN, R. A</creatorcontrib><description>Fifteen patients with previously untreated extensive non-small cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (4-DMDR) at the dose of 10 mg/m2/day x 5 days every 3 weeks with routine administration of antiemetic drugs. They received a median of two courses of treatment with the cumulative dose range from 50-712.5 mg/m2. One patient achieved partial remission with a duration of 14 weeks. Two patients had minor responses with durations of 14 and 24 weeks. Stable disease occurred in three patients (21, 22, and 27 weeks). Median survival was 33 weeks (range 3-73+ weeks). Toxicities were tolerable. Neutropenia (less than 1,000 mm3) occurred in only 16% of all treatment courses. Three patients developed correctable arrhythmias (two with atrial fibrillation and one with accelerated junctional rhythm). The cause of arrhythmia was unclear. No clinical evidence of congestive heart failure or decreased cardiac ejection fraction was observed. Nausea and vomiting were common but tolerable. Alopecia and mucositis were uncommon. Clinical pharmacokinetic studies were done in nine patients. However, plasma 4-DMDR levels were below the limit of detection (3 ng/ml). Because 4-DMDR has shown some activity in previously untreated E-NSCLC and the toxicities at this dose schedule are mild, we suggest that further studies of this drug at a higher dose in this schedule are indicated.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/BF00171988</identifier><identifier>PMID: 2166007</identifier><identifier>CODEN: INNDDK</identifier><language>eng</language><publisher>Dordrecht: Kluwer</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Biological Availability ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Chemotherapy ; Drug Evaluation ; Female ; Humans ; Idarubicin - pharmacokinetics ; Idarubicin - therapeutic use ; Idarubicin - toxicity ; Lung Neoplasms - drug therapy ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments</subject><ispartof>Investigational new drugs, 1990-01, Vol.8 (S1), p.S73-S78</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c270t-82889d14e61d10312f6e758776a2d769c7ddc6d22a0037ddb42844d78014b48d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=6911916$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2166007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>UMSAWASDI, T</creatorcontrib><creatorcontrib>FELDER, T. B</creatorcontrib><creatorcontrib>JEFFRIES, D</creatorcontrib><creatorcontrib>NEWMAN, R. A</creatorcontrib><title>Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>Fifteen patients with previously untreated extensive non-small cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (4-DMDR) at the dose of 10 mg/m2/day x 5 days every 3 weeks with routine administration of antiemetic drugs. They received a median of two courses of treatment with the cumulative dose range from 50-712.5 mg/m2. One patient achieved partial remission with a duration of 14 weeks. Two patients had minor responses with durations of 14 and 24 weeks. Stable disease occurred in three patients (21, 22, and 27 weeks). Median survival was 33 weeks (range 3-73+ weeks). Toxicities were tolerable. Neutropenia (less than 1,000 mm3) occurred in only 16% of all treatment courses. Three patients developed correctable arrhythmias (two with atrial fibrillation and one with accelerated junctional rhythm). The cause of arrhythmia was unclear. No clinical evidence of congestive heart failure or decreased cardiac ejection fraction was observed. Nausea and vomiting were common but tolerable. Alopecia and mucositis were uncommon. Clinical pharmacokinetic studies were done in nine patients. However, plasma 4-DMDR levels were below the limit of detection (3 ng/ml). Because 4-DMDR has shown some activity in previously untreated E-NSCLC and the toxicities at this dose schedule are mild, we suggest that further studies of this drug at a higher dose in this schedule are indicated.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biological Availability</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Chemotherapy</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Idarubicin - pharmacokinetics</subject><subject>Idarubicin - therapeutic use</subject><subject>Idarubicin - toxicity</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM1LAzEQxYMotVYv3oUcPAmrSTbNx1GL1UJBD3pessmsXdlmS7Jbuv-9KS0VhpmB95uB9xC6peSREiKfXuaEUEm1UmdoTKcyz4jg4hyNCRUyE1rLS3QV4y8hJNeSj9CIUSHS5Rj5z5WJgBcLHLveDbitMM8crKFbtbvBmd63oS9rW3ucahNgW7d9bAbc-y6A6cBh2HXgY70F7OoI-2--9Vlcm6bBFlJrev-DrfEWwjW6qEwT4eY4J-h7_vo1e8-WH2-L2fMys0ySLlNMKe0oB0EdJTlllQA5VVIKw5wU2krnrHCMmeQo7SVninMnFaG85MrlE_Rw-GtDG2OAqtiEem3CUFBS7DMr_jNL8N0B3vTlGtwJPYaU9PujbqI1TRWSlTqeMKEp1VTkf3yRc9I</recordid><startdate>19900101</startdate><enddate>19900101</enddate><creator>UMSAWASDI, T</creator><creator>FELDER, T. B</creator><creator>JEFFRIES, D</creator><creator>NEWMAN, R. A</creator><general>Kluwer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19900101</creationdate><title>Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer</title><author>UMSAWASDI, T ; FELDER, T. B ; JEFFRIES, D ; NEWMAN, R. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-82889d14e61d10312f6e758776a2d769c7ddc6d22a0037ddb42844d78014b48d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biological Availability</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Chemotherapy</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Idarubicin - pharmacokinetics</topic><topic>Idarubicin - therapeutic use</topic><topic>Idarubicin - toxicity</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>UMSAWASDI, T</creatorcontrib><creatorcontrib>FELDER, T. B</creatorcontrib><creatorcontrib>JEFFRIES, D</creatorcontrib><creatorcontrib>NEWMAN, R. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>UMSAWASDI, T</au><au>FELDER, T. B</au><au>JEFFRIES, D</au><au>NEWMAN, R. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>1990-01-01</date><risdate>1990</risdate><volume>8</volume><issue>S1</issue><spage>S73</spage><epage>S78</epage><pages>S73-S78</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><coden>INNDDK</coden><abstract>Fifteen patients with previously untreated extensive non-small cell lung cancer (E-NSCLC) were treated with oral 4-demethoxydaunorubicin (4-DMDR) at the dose of 10 mg/m2/day x 5 days every 3 weeks with routine administration of antiemetic drugs. They received a median of two courses of treatment with the cumulative dose range from 50-712.5 mg/m2. One patient achieved partial remission with a duration of 14 weeks. Two patients had minor responses with durations of 14 and 24 weeks. Stable disease occurred in three patients (21, 22, and 27 weeks). Median survival was 33 weeks (range 3-73+ weeks). Toxicities were tolerable. Neutropenia (less than 1,000 mm3) occurred in only 16% of all treatment courses. Three patients developed correctable arrhythmias (two with atrial fibrillation and one with accelerated junctional rhythm). The cause of arrhythmia was unclear. No clinical evidence of congestive heart failure or decreased cardiac ejection fraction was observed. Nausea and vomiting were common but tolerable. Alopecia and mucositis were uncommon. Clinical pharmacokinetic studies were done in nine patients. However, plasma 4-DMDR levels were below the limit of detection (3 ng/ml). Because 4-DMDR has shown some activity in previously untreated E-NSCLC and the toxicities at this dose schedule are mild, we suggest that further studies of this drug at a higher dose in this schedule are indicated.</abstract><cop>Dordrecht</cop><pub>Kluwer</pub><pmid>2166007</pmid><doi>10.1007/BF00171988</doi></addata></record>
fulltext fulltext
identifier ISSN: 0167-6997
ispartof Investigational new drugs, 1990-01, Vol.8 (S1), p.S73-S78
issn 0167-6997
1573-0646
language eng
recordid cdi_crossref_primary_10_1007_BF00171988
source MEDLINE; SpringerLink Journals
subjects Adult
Aged
Antineoplastic agents
Biological and medical sciences
Biological Availability
Carcinoma, Non-Small-Cell Lung - drug therapy
Chemotherapy
Drug Evaluation
Female
Humans
Idarubicin - pharmacokinetics
Idarubicin - therapeutic use
Idarubicin - toxicity
Lung Neoplasms - drug therapy
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
title Phase II study of 4-demethoxydaunorubicin in previously untreated extensive disease non-small cell lung cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T13%3A13%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20study%20of%204-demethoxydaunorubicin%20in%20previously%20untreated%20extensive%20disease%20non-small%20cell%20lung%20cancer&rft.jtitle=Investigational%20new%20drugs&rft.au=UMSAWASDI,%20T&rft.date=1990-01-01&rft.volume=8&rft.issue=S1&rft.spage=S73&rft.epage=S78&rft.pages=S73-S78&rft.issn=0167-6997&rft.eissn=1573-0646&rft.coden=INNDDK&rft_id=info:doi/10.1007/BF00171988&rft_dat=%3Cpubmed_cross%3E2166007%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2166007&rfr_iscdi=true